Understanding Zimmer Biomet Holdings – A Fundamental Analysis

By Blake Campbell • Thursday, September 05 15:08 • Permanent Link

Zimmer Biomet logged a -8.4% change during today's afternoon session, and is now trading at a price of $104.92 per share. The S&P 500 index moved -0.0%. ZBH's trading volume is 3,459,776 compared to the stock's average volume of 1,499,537.

Zimmer Biomet trades -17.07% away from its average analyst target price of $126.52 per share. The 25 analysts following the stock have set target prices ranging from $107.0 to $145.0, and on average have given Zimmer Biomet a rating of hold.

If you are considering an investment in ZBH, you'll want to know the following:

Zimmer Biomet's current price is 29.8% above its Graham number of $80.84, which implies that at its current valuation it does not offer a margin of safety
Zimmer Biomet has moved -5.0% over the last year, and the S&P 500 logged a change of 24.0%
Based on its trailing earnings per share of 4.79, Zimmer Biomet has a trailing 12 month Price to Earnings (P/E) ratio of 21.9 while the S&P 500 average is 28.21
ZBH has a forward P/E ratio of 12.1 based on its forward 12 month price to earnings (EPS) of $8.66 per share
The company has a price to earnings growth (PEG) ratio of 2.06 — a number near or below 1 signifying that Zimmer Biomet is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 1.69 compared to its sector average of 3.69
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
Based in Warsaw, the company has 18,000 full time employees and a market cap of $21.37 Billion. Zimmer Biomet currently returns an annual dividend yield of 0.8%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.